Literature DB >> 29370977

Severe dysautonomia as a main feature of anti-GAD encephalitis: Report of a paediatric case and literature review.

Nedia Ben Achour1, Thouraya Ben Younes2, Ibtihel Rebai3, Melika Ben Ahmed4, Ichraf Kraoua3, Ilhem Ben Youssef-Turki3.   

Abstract

INTRODUCTION: Anti-glutamic acid decarboxylase (anti-GAD65) antibodies are a rare cause of autoimmune encephalitis. This entity is mainly recognized in adults and very few cases were reported in children. We report on a paediatric case of anti-GAD encephalitis with severe presentation and uncontrollable dysautonomia. CASE STUDY: A 9-year-old girl was referred to our department for refractory seizures and behavioral disturbances. Brain magnetic resonance imaging (MRI) was normal. Repeat screening for antineuronal antibodies showed negative results for anti-NMDA receptor antibodies but positive results for anti-GAD65 with a low positivity of anti-Ma2 antibodies. Although a transient improvement was noticed after immunomodulatory treatment, the patient developed severe intractable autonomic imbalance including dysrythmia, alternating bradycardia/tachycardia, hypotension/hypertension, hypothermia/hyperthermia and hyperhidrosis. She deceased six months after onset.
CONCLUSION: Our report intends to raise awareness of autoimmune encephalitis with anti-GAD65 antibodies which may involve extralimbic brain regions and manifest with fatal dysautonomia. We highlight the need for prompt diagnosis and aggressive management for this underdiagnosed entity in children.
Copyright © 2018 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-glutamic acid decarboxylase antibodies; Autoimmune; Dysautonomia; Limbic encephalitis; Refractory seizures; anti-Ma2

Mesh:

Substances:

Year:  2018        PMID: 29370977     DOI: 10.1016/j.ejpn.2018.01.004

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  8 in total

1.  Pediatric Autoimmune Encephalitis: Practical Aspects.

Authors:  Mihaela Roxana Ioghen; Diana Anamaria Epure; Raluca Ioana Teleanu
Journal:  Maedica (Bucur)       Date:  2020-12

2.  Autoimmune encephalitis and epilepsy: evolving definition and clinical spectrum.

Authors:  Joo Hee Seo; Yun-Jin Lee; Ki Hyeong Lee; Elakkat Gireesh; Holly Skinner; Michael Westerveld
Journal:  Clin Exp Pediatr       Date:  2019-08-16

3.  Clinical Characteristics and Short-Term Prognosis of Autoimmune Encephalitis: A Single-Center Cohort Study in Changsha, China.

Authors:  Shuwen Deng; Ke Qiu; Hui Liu; Xiaomei Wu; Qiang Lei; Wei Lu
Journal:  Front Neurol       Date:  2019-05-24       Impact factor: 4.003

4.  Case Report: Autoimmune Encephalitis Associated With Anti-glutamic Acid Decarboxylase Antibodies: A Pediatric Case Series.

Authors:  Changhong Ren; Haitao Ren; Xiaotun Ren; Weihua Zhang; Jiuwei Li; Lifang Dai; Hongzhi Guan; Fang Fang
Journal:  Front Neurol       Date:  2021-04-12       Impact factor: 4.003

Review 5.  Immunotherapy for Refractory Autoimmune Encephalitis.

Authors:  Jiawei Yang; Xueyan Liu
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

6.  Autoimmune Encephalitis in Tunisia: Report of a Pediatric Cohort.

Authors:  Bissene Douma; Thouraya Ben Younes; Hanene Benrhouma; Zouhour Miladi; Imen Zamali; Aida Rouissi; Hedia Klaa; Ichraf Kraoua; Melika Ben Ahmed; Ilhem Ben Youssef Turki
Journal:  J Immunol Res       Date:  2021-05-10       Impact factor: 4.818

7.  Intravenous methylprednisolone or immunoglobulin for anti-glutamic acid decarboxylase 65 antibody autoimmune encephalitis: which is better?

Authors:  Tao-Ran Li; Yu-Di Zhang; Qun Wang; Xiao-Qiu Shao; Zhi-Mei Li; Rui-Juan Lv
Journal:  BMC Neurosci       Date:  2020-03-30       Impact factor: 3.288

8.  Neurological Autoimmunity Associated With Homer-3 Antibody: A Case Series From China.

Authors:  Mange Liu; Haitao Ren; Siyuan Fan; Weihe Zhang; Yao Xu; Weili Zhao; Hongzhi Guan
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-09-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.